The purpose of the study was to evaluate the cost-effectiveness of capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX4) as first-line or ...

A prospective multicenter phase II trial of total neoadjuvant therapy for locally advanced rectal cancer in JAPAN: ENSEMBLE-1 study. This is an ASCO Meeting Abstract from the 2024 ASCO ...

In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic ...

PFS general approach 8.0 9.4 HR 0.83 (97.5% CI 0.72–0.95), p=0.0023 PFS on treatment approach 7.9 10.4 HR 0.63 (97.5% CI 0.52–0.75), p<0.0001 PFS based on IRC dataset 8.6 11.1 HR 0.70 (97.5% CI 0.58–0 ...

CHICAGO— Adjuvant capecitabine and oxaliplatin (XELOX) demonstrated superior efficacy when compared with observation alone following D2 gastrectomy for gastric cancer, according to study results ...

October 3, 2006 (Istanbul) — Experts at the 31st Congress of the European Society for Medical Oncology (ESMO) were calling for a change in the standard of care for first-line treatment of metastatic ...

After surgery for advanced gastric cancer, treatment with capecitabine and oxaliplatin (XELOX) cuts the risk for death by 34% over 5 years, compared with surgery alone, according to new data from the ...

The International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaboration found evidence to support the noninferiority of 3 versus 6 months oxaliplatin-based adjuvant therapy for ...

Please provide your email address to receive an email when new articles are posted on . The addition of trastuzumab to the standard first-line regimen of capecitabine plus oxaliplatin created a highly ...

Roche Release: Results Show XELOX Provides Equivalent Overall Patient Survival Compared To FOLFOX In Advanced Colorectal Cancer NUTLEY, N.J., Jan. 22 -- Overall survival results from an international, ...